Takeda Pharmaceutical Acquires Intellikine for $310,000,000
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=7c3decc5-ad56-4290-ab23-4154fb33d394&Preview=1 -
Date
12/21/2011 -
Company Name
Intellikine -
Mailing Address
10931 N. Torrey Pines Rd. La Jolla, CA 92037 -
Company Description
Intellikine is a leader in the discovery and development of novel, small molecule therapies targeting the PI3K/Akt/mTOR pathway. -
Website
http://www.intellikine.com -
Transaction Type
M&A -
Transaction Amount
$310,000,000 -
Transaction Round
-
Proceeds Purposes
-
M&A Terms
Under the agreement, Takeda America Holdings will acquire Intellikine for $190 million upfront and up to $120 million in additional potential clinical development milestone payments.
